HOME >> BIOLOGY >> NEWS
JCI table of contents, March 9, 2006

EDITOR'S PICK

Fat rats reveal why short-term overeating can lead to obesity and diabetes

Obesity is due to a mismatch between the number of calories we consume and the amount of physical activity we undertake. In the brain, a region called the hypothalamus control ours eating behavior through its metabolism of fat molecules called fatty acids. Interestingly, eating too much in the short-term can result in a severe drop in the ability of the body (and brain) to be satisfied by fat and to control blood sugar levels. In a study appearing online on March 9 in advance of print publication in the April issue of the Journal of Clinical Investigation, Luciano Rossetti and colleagues at Albert Einstein College of Medicine in New York report that inhibiting an enzyme in the liver called carnitine palmitoyltransferase-1 (CPT1A), which is involved in metabolizing fatty acids, inhibits feeding. The researchers placed normal rats on a lard-based diet, which stimulated the animals to voluntarily overeat and gain weight. When the researchers inhibited CPT1A by delivering special molecules called "ribozymes" into the brain of the rats, the animals ate dramatically less. The treatment also improved the blood sugar levels of these animals, who suffered from a common metabolic impairment known as insulin resistance, in which the body is unable to respond properly to insulin. The authors report that this animal model of diet-induced obesity and insulin resistance displayed defective adaptation to an increase in fat availability coupled with a severe impairment in the ability of the brain to sense fat intake. Further studies will be required to establish the critical role of this biochemical pathway in nutrient sensing in other animal models and, critically, in humans.

TITLE: Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats

AUTHOR CONTACT: Luciano Rossetti
Albert Einstein College of
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
9-Mar-2006


Page: 1 2 3 4 5 6

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2019)... ... May 21, 2019 , ... At their May 16 ... Tissue Engineered Medical Products (TEMPs) of the American Society for Testing and Materials ... Gaining this approval was the next step in the company’s plan to establish ...
(Date:5/14/2019)... ... May 13, 2019 , ... BioMedGPS is excited to ... Pre-EWMA 2019 event at Gothenburg’s Universeum Aquarium. Guests will be treated to an ... Advanced Wound Care. , SmartTRAK’s Advanced Wound Care Experts will serve as panelists. ...
(Date:5/8/2019)... (PRWEB) , ... May 08, 2019 , ... ... – has successfully leveraged the support services provided by Medrio , the ... a clinical trial sponsor agreement. , By collaborating to position high-quality CRO ...
Breaking Biology News(10 mins):
(Date:4/15/2019)... LOVELAND, Ohio (PRWEB) , ... April 15, 2019 ... ... and oligomers, has completed construction of a $2 million bench plant expansion to ... represents an important step in the design and construction of Sirrus’ full-scale production ...
(Date:4/9/2019)... ... April 09, 2019 , ... USDM Life Sciences ... life sciences organizations to accelerate innovation and maximize productivity, announces that nearly 100 ... 12 months. , USDM’s Cloud Assurance is a managed subscription service ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global Securities , an ... equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). , S1 has ... at female hypoactive sexual dysfunction disorder and is ready to begin phase 2b trials. ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced ... proceeded with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility ... top of the $1.7 million already awarded by CARB-X. The additional $1.7M will ...
Breaking Biology Technology:
Cached News: